major cause of perinatal mortality in Britain. In the 1950s, before the development of exchange transfusion, amniocentesis, intrauterine transfusion, and early induction of labour, mortality from stillbirths and neonatal deaths was about 1 5 per 1000 births, equivalent to well over 1000 deaths a year. After the introduction of the above technical improvements there was a gradual reduction in mortality such that by 1969, 708 deaths due to Rh(D) haemolytic disease of the newborn were recorded in Britain (13 per million population a year).'2 This achievement was not dramatic and represented a considerable workload for obstetricians and paediatricians. The breakthrough which accelerated the improvement in fetal mortality came in the 1970s with the introduction of anti-D immunoglobulin prophylaxis, and by 1979 mortality had been reduced to 105 stillbirths and postnatal deaths. The latest statistics (1983) have been analysed in detail at p 17 by Clarke, Mollison, and Whitfield and they identify 34 deaths (stillbirths and postnatal deaths) due to Rh(D) haemolytic disease of the newborn (5 4 per 100 000 births). Thus deaths from this disease now contribute 0-33% to the combined stillbirth and perinatal mortality rates (1614 per 100000 births). Even given the inaccuracy of official statistics it would seem that Rh(D) haemolytic disease is no longer a frequent cause of death.
Nevertheless, the continued appearance of new cases of immunisation of women is disturbing. 3 The mortality statistics obscure the fact that there are still appreciable numbers of affected babies being saved by medical intervention and who would have died 10 years ago. Furthermore, deaths from haemolytic disease of the newborn occurring before 28 weeks would be recorded as abortions and not included in the above statistics.
Over the past five to 10 years new cases of immunisation have appeared at the rate of some 600-800 a year, and analysis of the reasons why the present prophylaxis programme has failed to eliminate haemolytic disease of the newborn shows that in the year of study (1978) some 800 new cases (14 6 per million population a year) of Rh(D) sensitisation appeared in Britain as a whole.4 About 140 of these mothers had become immunised before the anti-D immunoglobulin era; this cohort will decrease and be beyond reproductive age by the year 2000. The current prophylaxis programme, therefore, still fails to prevent some 600-700 Rh(D) negative women (12 4 Mortality associated with fetoscopy is 3-5%.
Intensive plasma exchange to remove maternal anti-D immunoglobulin should also be considered in this group of highly immunised women. Plasma exchange of 3-4 litres may he required up to three or more times a week for the duration of the pregnancy if the level of anti-D is to be reduced. S 6 In the absence of immunosuppression there may be a rapid rebound of antibody concentrations which cannot be controlled even with daily plasma exchange, and fetal death ensues. The effects of plasma exchange on amniocentesis are less convincing, showing that there is sufficient residual circulating maternal antibody to cross the placenta and affect the fetus. Evaluation of reported success in using plasma exchange is difficult because results are compared with historical controls, and, as noted above, other important advances have contributed to the improved fetal mortality from haemolytic disease of the newborn. Selection criteria may not be particularly stringent and in many cases it is apparent that the babies already had an excellent chance of survival with conventional management. Plasma exchange is not to be undertaken lightly because the mother is being put at risk as well as the baby, and maternal deaths attributable to exchange with fresh frozen plasma have been reported. ' 
